Findings

What do systematic reviews say?

9 questions · 9 findings · 1 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 5 · 55.6%GRADE not reported 1 · 11.1%Very low 2 · 22.2%Low 1 · 11.1%Moderate 0 · 0%High 0 · 0%

Acetyl‐L‐carnitine vs placebo

Pain at 6 months or more; all doses Assessed by change from baseline, using a 0‐ to 100‐mm VAS, where higher scores indicate more pain) · people with diabetic peripheral neuropathy

1 finding from 1 review

Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 540 participants
Very low

Acetyl‐L‐carnitine vs methylcobalamin

Impairment of sensation Assessed by quantitative sensory testing ‐ thermal threshold ‐ at 6 months or more · the treatment of diabetic peripheral neuropathy

The review found no eligible studies for this question.

1 finding from 1 review

Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Acetyl‐L‐carnitine vs methylcobalamin

Symptom quality and severity Assessed by NSS score (range of possible scores 0 to 9; higher scores indicate more symptoms) · the treatment of diabetic peripheral neuropathy

1 finding from 1 review

Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 232 participants
Low

Acetyl‐L‐carnitine vs placebo

Functional impairment and disability Assessed by NIS or NDS at 6 months or more · people with diabetic peripheral neuropathy

The review found no eligible studies for this question.

1 finding from 1 review

Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Acetyl‐L‐carnitine vs placebo

Impairment of sensation Assessed by quantitative sensory testing ‐ vibration perception threshold ‐ at 6 months or more · people with diabetic peripheral neuropathy

1 finding from 1 review

Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 341 participants
Very low

Acetyl‐L‐carnitine vs placebo

Impairment of sensation Assessed by quantitative sensory testing ‐ thermal threshold ‐ at 6 months or more · people with diabetic peripheral neuropathy

The review found no eligible studies for this question.

1 finding from 1 review

Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Acetyl‐L‐carnitine vs placebo

Symptom quality and severity Assessed by change in symptom score on a validated screening questionnaire (NSS or MNSI) at 6 months or more · people with diabetic peripheral neuropathy

1 finding from 1 review

Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy 2019 · Cochrane Headline outcomes only
no estimate extracted
2 participants
GRADE not reported

Acetyl‐L‐carnitine vs methylcobalamin

Pain at 6 months or more · the treatment of diabetic peripheral neuropathy

The review found no eligible studies for this question.

1 finding from 1 review

Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Acetyl‐L‐carnitine vs methylcobalamin

Impairment of sensation Assessed by quantitative sensory testing ‐ vibration perception threshold ‐ at 6 months or more · the treatment of diabetic peripheral neuropathy

The review found no eligible studies for this question.

1 finding from 1 review

Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found